2023
|
Sign up to set email alerts
Recent advances in epicutaneous immunotherapy and potential applications in food allergy
Abstract: Given the potent immunological properties of the skin, epicutaneous immunotherapy (EPIT) emerges as a promising treatment approach for inducing immune tolerance, particularly for food allergies. Targeting the highly immunocompetent, non-vascularized epidermis allows for the application of microgram amounts of allergen while significantly reducing the risk of allergen passage into the bloodstream, thus limiting systemic allergen exposure and distribution. This makes EPIT highly suitable for the treatment of pot… Show more
23
0
28
0
Search citation statements
Order By: Relevance
Paper Sections
Select...
22
2
1
0
Citation Types
0
28
0
0
Year Published
Range
2024
20242026
2026Publication Types
Select...
21
2
1
Relationship
1
23
Authors
Journals
Cited by 23 publications
(28 citation statements)
References 155 publications
0
28
0
0
Order By: Relevance
Smart CitationsHow the paper below cites the one you are viewing
“…This route aims to exploit the immunoregulatory capacity of cutaneous antigen-presenting cells while minimizing systemic allergen exposure. EPIT has consistently shown a favorable safety profile, with most adverse events limited to local skin reactions [73].…”
Section: Results
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…This route aims to exploit the immunoregulatory capacity of cutaneous antigen-presenting cells while minimizing systemic allergen exposure. EPIT has consistently shown a favorable safety profile, with most adverse events limited to local skin reactions [73].…”
Section: Results
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Epicutaneous and microneedle-based allergen delivery have recently shown promise in promoting tolerogenic DC phenotypes. Furthermore, targeting antigens through specific receptors, such as Langerin or DEC-205, on skin APCs, may provide novel vaccine strategies that achieve long-term immune regulation instead of pathogenic inflammation [167][168][169].…”
Section: Challenges and Emerging Concepts In Cutaneous Apcs Research ...
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…New treatments are emerging alongside traditional avoidance. Clinical trials have proposed EPIT as a promising therapeutic approach, particularly for peanut allergy in younger patients [ 49 , 50 ]. EPIT involves applying a patch to the skin (the most advanced platform to date is called Viaskin) that contains a small amount of the allergenic protein.…”
Section: Oral Immunotherapy and Current Treatments
mentioning
confidence: 99%
“…EPIT involves applying a patch to the skin (the most advanced platform to date is called Viaskin) that contains a small amount of the allergenic protein. The goal is to expose the skin's immune cells to the allergen in a controlled manner, thereby promoting immune tolerance rather than triggering an allergic reaction [ 50 ]. Currently, there are no head‐to‐head studies comparing OIT and EPIT.…”
Section: Oral Immunotherapy and Current Treatments
mentioning
confidence: 99%
“…Additionally, the EPIT therapeutic approach highlights the skin as a target organ for inducing immune tolerance. It operates through a distinct skin‐driven pathway in which allergens are captured by LCs and dermal dendritic cells that migrate to skin‐draining lymph nodes to promote Tregs response [ 50 , 63 ]. EPIT appears to gradually induce long‐lasting, multifunctional Tregs with broad tissue‐homing potential and stable epigenetic reprogramming (such as sustained Foxp3 demethylation and Gata3 silencing) [ 64 ].…”
Section: Epithelial Barrier In Allergic Sensitization To Food Allergens
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…This route aims to exploit the immunoregulatory capacity of cutaneous antigen-presenting cells while minimizing systemic allergen exposure. EPIT has consistently shown a favorable safety profile, with most adverse events limited to local skin reactions [73].…”
Section: Results
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Epicutaneous and microneedle-based allergen delivery have recently shown promise in promoting tolerogenic DC phenotypes. Furthermore, targeting antigens through specific receptors, such as Langerin or DEC-205, on skin APCs, may provide novel vaccine strategies that achieve long-term immune regulation instead of pathogenic inflammation [167][168][169].…”
Section: Challenges and Emerging Concepts In Cutaneous Apcs Research ...
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…New treatments are emerging alongside traditional avoidance. Clinical trials have proposed EPIT as a promising therapeutic approach, particularly for peanut allergy in younger patients [ 49 , 50 ]. EPIT involves applying a patch to the skin (the most advanced platform to date is called Viaskin) that contains a small amount of the allergenic protein.…”
Section: Oral Immunotherapy and Current Treatments
mentioning
confidence: 99%
“…EPIT involves applying a patch to the skin (the most advanced platform to date is called Viaskin) that contains a small amount of the allergenic protein. The goal is to expose the skin's immune cells to the allergen in a controlled manner, thereby promoting immune tolerance rather than triggering an allergic reaction [ 50 ]. Currently, there are no head‐to‐head studies comparing OIT and EPIT.…”
Section: Oral Immunotherapy and Current Treatments
mentioning
confidence: 99%
“…Additionally, the EPIT therapeutic approach highlights the skin as a target organ for inducing immune tolerance. It operates through a distinct skin‐driven pathway in which allergens are captured by LCs and dermal dendritic cells that migrate to skin‐draining lymph nodes to promote Tregs response [ 50 , 63 ]. EPIT appears to gradually induce long‐lasting, multifunctional Tregs with broad tissue‐homing potential and stable epigenetic reprogramming (such as sustained Foxp3 demethylation and Gata3 silencing) [ 64 ].…”
Section: Epithelial Barrier In Allergic Sensitization To Food Allergens
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…This route aims to exploit the immunoregulatory capacity of cutaneous antigen-presenting cells while minimizing systemic allergen exposure. EPIT has consistently shown a favorable safety profile, with most adverse events limited to local skin reactions [73].…”
Section: Results
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Epicutaneous and microneedle-based allergen delivery have recently shown promise in promoting tolerogenic DC phenotypes. Furthermore, targeting antigens through specific receptors, such as Langerin or DEC-205, on skin APCs, may provide novel vaccine strategies that achieve long-term immune regulation instead of pathogenic inflammation [167][168][169].…”
Section: Challenges and Emerging Concepts In Cutaneous Apcs Research ...
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…New treatments are emerging alongside traditional avoidance. Clinical trials have proposed EPIT as a promising therapeutic approach, particularly for peanut allergy in younger patients [ 49 , 50 ]. EPIT involves applying a patch to the skin (the most advanced platform to date is called Viaskin) that contains a small amount of the allergenic protein.…”
Section: Oral Immunotherapy and Current Treatments
mentioning
confidence: 99%
“…EPIT involves applying a patch to the skin (the most advanced platform to date is called Viaskin) that contains a small amount of the allergenic protein. The goal is to expose the skin's immune cells to the allergen in a controlled manner, thereby promoting immune tolerance rather than triggering an allergic reaction [ 50 ]. Currently, there are no head‐to‐head studies comparing OIT and EPIT.…”
Section: Oral Immunotherapy and Current Treatments
mentioning
confidence: 99%
“…Additionally, the EPIT therapeutic approach highlights the skin as a target organ for inducing immune tolerance. It operates through a distinct skin‐driven pathway in which allergens are captured by LCs and dermal dendritic cells that migrate to skin‐draining lymph nodes to promote Tregs response [ 50 , 63 ]. EPIT appears to gradually induce long‐lasting, multifunctional Tregs with broad tissue‐homing potential and stable epigenetic reprogramming (such as sustained Foxp3 demethylation and Gata3 silencing) [ 64 ].…”
Section: Epithelial Barrier In Allergic Sensitization To Food Allergens
mentioning
confidence: 99%
Abstract